Video

Dr. Schaider Discusses Drug Resistance for Melanoma

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

According to Schaider, adaptive drug resistance occurs at the beginning of treatment. Drug resistance generally occurs in the first 3 to 6 weeks.

More studies need to be conducted to determine why the cells become resistant to certain treatments, states Schaider.

Related Videos
Odzer on ERBB2 Copy Number Ratio as a Predictive Biomarker in HER2+ Breast Cancer
Robert M. Rifkin, MD, FACP
Renier Brentjens, MD, PhD,
Jian Zhang, MD
Carsten Niemann, MD, PhD, chief physician, and head of Laboratory at the Rigshospitalet Copenhagen University Hospital.
Jae Park, MD
David A. Braun, MD, PhD
Bradley McGregor, MD,
Francisco J. Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine – Lymphoma, director, Lymphoma Research, head, Lymphoma Translational Research Lab, associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington